peptides for libido
one peptide cleared fda for low libido in women. central melanocortin, not vascular.
one peptide on this page has an fda libido-related indication. pt-141, branded vyleesi, approved june 21 2019 for acquired generalized hypoactive sexual desire disorder in premenopausal women. n=1247 across reconnect 1 and 2, ~25% fsfi-desire improvement vs placebo. it acts centrally through melanocortin receptors, not vascular smooth muscle, which is why it works on the desire axis where pde5 drugs do not, and why it has its own side-effect profile (transient blood-pressure rise, nausea, focal hyperpigmentation).
everything else in the libido category sits at less mature evidence. kisspeptin-family research is real and published in jama network open, but the hsdd and ivf trials used kisspeptin-54 while vendors sell kp-10. oxytocin was the first peptide hormone ever synthesized but only obstetric labels exist. hcg, gonadorelin, and triptorelin are reproductive-axis drugs that get reclassified as libido peptides without the indication to match.
the direct libido cluster.
compounds whose published evidence or mechanism sits closest to sexual desire and arousal rather than general hormone support.
- pt-141 (tier A) — bremelanotide. fda-approved as vyleesi june 21 2019 for hsdd in premenopausal women. reconnect 1 + 2 enrolled n=1247.
- melanotan-ii (tier A) — non-selective melanocortin agonist with pigment and arousal effects. parent compound from which bremelanotide was derived.
- kisspeptin-10 (tier B) — kp-10. 10-amino-acid c-terminal fragment of kisspeptin. master hpg-axis trigger.
- oxytocin (tier B) — cyclic nonapeptide, fda-approved (pitocin) for obstetric use only.
hormone support is not the same claim.
compounds that affect reproductive signaling, fertility, or endocrine axes. libido shows up in user discussion. the published indications target gonadal axis function, not desire.
- hcg (tier S) — lh analog. fda-approved for hypogonadotropic hypogonadism, fertility induction, and cryptorchidism. brand names: pregnyl, novarel, ovidrel.
- gonadorelin (tier C) — synthetic gnrh. 2-4 minute plasma half-life. pulsatile dosing defines the pharmacology.
- triptorelin (tier C) — gnrh agonist. fda-approved as trelstar for prostate cancer and as triptodur for central precocious puberty.
specific-question reference.
which peptide has an fda-approved libido indication?
one. pt-141, as bremelanotide/vyleesi, approved june 21 2019 for acquired generalized hypoactive sexual desire disorder in premenopausal women. reconnect 1 and 2 enrolled n=1247. ~25% fsfi-desire improvement vs placebo. the indication is specific. it is not a universal libido prescription, and it is not approved in men.
is kp-10 the same as kp-54 in the published trials?
no. this is the bait-and-switch in the category. the imperial college london trials (waljit dhillo, jama network open) that produced the 56% tumescence-increase reading and fmri changes used kisspeptin-54. the ivf-trigger work also used kp-54 (~23% clinical pregnancy with lower ohss vs hcg). gray-market vendors sell kp-10. they share the c-terminal receptor-binding motif, but half-life and trial portfolio differ. kp-10 has its own mechanistic literature (george et al. edinburgh group) but is not the molecule from the headline hsdd readings.
is pt-141 the same as melanotan-ii?
no. they share melanocortin biology, but pt-141 was developed through palatin technologies as a drug product with reconnect 1 + 2 and an fda label. melanotan-ii is a broader non-selective receptor agonist with tanning and arousal effects but no drug-development pedigree.
where do hcg, gonadorelin, and triptorelin fit?
reproductive-axis drugs. fertility induction, testosterone-axis preservation, gonadal suppression in oncology and pediatrics. libido shows up in user discussion but is an indirect, person-specific endpoint, not an indication.
why is oxytocin hard to summarize as a libido peptide?
the only fda labels are obstetric (pitocin, 1962). seventy years of off-label phase-2 work covers autism, ptsd, social anxiety, anorgasmia. context and dose shift the effect pattern. the popular-press nickname does not compress cleanly.
what the safety literature reports.
what does the pt-141 / vyleesi label-defined safety profile look like?
transient blood-pressure increase (the reason palatin abandoned the intranasal-ed program in 2007 and re-engineered for subcutaneous female hsdd), nausea, vomiting, headache, focal hyperpigmentation. label contraindication: uncontrolled hypertension or known cardiovascular disease.
what is the safety difference with melanotan-ii?
melanotan-ii is a non-selective melanocortin agonist with the same nausea and blood-pressure signal plus broader pigment effects, including new and changing nevi reported in case literature. no fda label, no formal safety review, no controlled long-term human trial.
what safety issue matters for kisspeptin-family compounds?
the published imperial college kp-54 trials report a clean acute safety profile in small-n single-dose work. long-term and high-dose data are not in the published record. kp-10 has its own profile that is not interchangeable with kp-54.
what safety issue matters for reproductive-axis compounds?
hormonal feedback. continuous gnrh exposure desensitizes the axis (the mechanism by which triptorelin suppresses gonadal function). pulsatile dosing stimulates it. same molecule, opposite effect depending on pattern. that is clinical endocrinology, not search-result territory.
related comparisons
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.